NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.43 -0.72 (-3.57 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$20.15
Today's Range$19.32 - $20.65
52-Week Range$5.47 - $23.50
Volume2.13 million shs
Average Volume1.43 million shs
Market Capitalization$2.10 billion
P/E Ratio-18.16
Dividend YieldN/A
Beta1.99

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Debt-to-Equity RatioN/A
Current Ratio2.97
Quick Ratio2.91

Price-To-Earnings

Trailing P/E Ratio-18.16
Forward P/E Ratio-21.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$128.37 million
Price / Sales15.75
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book5.57

Profitability

EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-64.39%
Return on Equity-29.47%
Return on Assets-19.00%

Miscellaneous

Employees215
Outstanding Shares104,060,000

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals (NASDAQ:SPPI) posted its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.19. The biotechnology company had revenue of $30.50 million for the quarter, compared to analyst estimates of $25.68 million. Spectrum Pharmaceuticals had a negative net margin of 64.39% and a negative return on equity of 29.47%. Spectrum Pharmaceuticals's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.14) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

What price target have analysts set for SPPI?

4 Wall Street analysts have issued 12-month target prices for Spectrum Pharmaceuticals' stock. Their predictions range from $25.00 to $33.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $29.00 in the next twelve months. View Analyst Ratings for Spectrum Pharmaceuticals.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 11,563,282 shares, an increase of 12.4% from the March 30th total of 10,288,002 shares. Based on an average daily trading volume, of 3,296,568 shares, the short-interest ratio is presently 3.5 days. Approximately 12.3% of the shares of the company are short sold.

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 50)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 42)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
  • Mr. Keith McGahan, Sr. VP & Chief Legal Officer

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News articles about SPPI stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of 0.17 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 48.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.48%), SHROTRIYA RAJESH C MD (5.92%), Dimensional Fund Advisors LP (2.32%), Northern Trust Corp (1.04%), Wells Fargo & Company MN (0.99%) and Principal Financial Group Inc. (0.69%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which major investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, ClariVest Asset Management LLC, California Public Employees Retirement System, Royal Bank of Canada, American International Group Inc., Public Employees Retirement Association of Colorado and State of Tennessee Treasury Department. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, BNP Paribas Arbitrage SA, DekaBank Deutsche Girozentrale, Wells Fargo & Company MN, Iguana Healthcare Management LLC, Harvey Partners LLC and Mackay Shields LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $19.43.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $2.10 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Spectrum Pharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 49.25%. The high price target for SPPI is $33.00 and the low price target for SPPI is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$25.40$24.25
Price Target Upside: 49.25% upside31.82% upside15.45% upside26.11% upside

Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History

Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018HC WainwrightBoost Price TargetPositive ➝ Buy$33.00HighView Rating Details
12/18/2017B. RileyInitiated CoverageBuy ➝ Buy$26.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/AView Rating Details
10/20/2017Jefferies GroupBoost Price TargetBuy$25.00N/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/15/2016Royal Bank of CanadaSet Price TargetBuy$11.00 ➝ $10.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings History and Estimates Chart

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings Estimates

2018 EPS Consensus Estimate: ($1.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.35)($0.31)($0.33)
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.33)($0.33)($0.33)
Q4 20181($0.33)($0.33)($0.33)

Spectrum Pharmaceuticals (NASDAQ SPPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.35)($0.16)$25.68 million$30.50 millionViewN/AView Earnings Details
3/6/2018Q4 2017($0.25)($0.29)$33.18 million$28.57 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.16)($0.22)$33.27 million$36.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.27)($0.26)$30.50 million$34.30 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.20)($0.18)$32.23 million$29.10 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.27)($0.2190)$31.13 million$35.24 millionViewListenView Earnings Details
11/14/2016Q3 2016($0.30)($0.22)$29.53 million$33.39 millionViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)$49.88 million$38.67 millionViewN/AView Earnings Details
2/21/2013Q4 2012$0.16$0.18ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
8/8/2012Q2 2012$0.31$0.34ViewN/AView Earnings Details
4/26/2012Q1 2012$0.28$0.35ViewN/AView Earnings Details
3/1/2012Q4 2011$0.28$0.13ViewN/AView Earnings Details
10/28/2011Q3 2011$0.09$0.29ViewN/AView Earnings Details
8/4/2011Q2 2011$0.13$0.13ViewN/AView Earnings Details
5/4/2011Q1 2011$0.01$0.33ViewN/AView Earnings Details
3/10/2011Q4 2010($0.04)$0.14ViewN/AView Earnings Details
11/4/2010Q3 2010($0.22)($0.07)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.20)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.15)($0.78)ViewN/AView Earnings Details
4/5/2010Q4 2009($0.20)($0.19)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.20)($0.17)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.14)($0.28)ViewN/AView Earnings Details
5/18/2009Q1 2009($0.11)$0.02ViewN/AView Earnings Details
3/31/2009Q4 2008($0.17)($0.12)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.32)($0.28)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.34)$0.34ViewN/AView Earnings Details
5/13/2008Q1 2008($0.40)($0.28)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.38)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.35%
Institutional Ownership Percentage: 77.11%
Insider Trading History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Stuart Mitchell KrassnerDirectorSell21,113$18.94$399,880.2257,944View SEC Filing  
5/14/2018Rajesh C Md ShrotriyaDirectorSell24,014$18.38$441,377.32200,652View SEC Filing  
5/14/2018Thomas J RigaCOOSell3,290$18.10$59,549.00View SEC Filing  
5/11/2018Rajesh C Md ShrotriyaDirectorSell30,000$17.55$526,500.00200,652View SEC Filing  
5/9/2018Rajesh C Md ShrotriyaDirectorSell30,000$16.21$486,300.00200,652View SEC Filing  
5/7/2018Rajesh C Md ShrotriyaDirectorSell30,000$15.98$479,400.00200,652View SEC Filing  
5/4/2018Rajesh C Md ShrotriyaDirectorSell90,000$16.28$1,465,200.00200,652View SEC Filing  
5/1/2018Rajesh C Md ShrotriyaDirectorSell90,000$16.43$1,478,700.00200,652View SEC Filing  
4/27/2018Rajesh C Md ShrotriyaDirectorSell30,000$17.17$515,100.00200,652View SEC Filing  
4/25/2018Rajesh C Md ShrotriyaDirectorSell30,000$17.26$517,800.00200,652View SEC Filing  
4/23/2018Rajesh C Md ShrotriyaDirectorSell30,000$18.37$551,100.00200,652View SEC Filing  
4/20/2018Rajesh C Md ShrotriyaDirectorSell30,000$18.67$560,100.00200,652View SEC Filing  
4/18/2018Rajesh C Md ShrotriyaDirectorSell90,000$19.00$1,710,000.00200,652View SEC Filing  
4/17/2018Joseph W TurgeonCEOSell11,565$19.00$219,735.00316,509View SEC Filing  
4/16/2018Rajesh C Md ShrotriyaDirectorSell30,000$18.72$561,600.00200,652View SEC Filing  
4/16/2018Thomas J RigaCOOSell3,900$18.60$72,540.00254,694View SEC Filing  
4/13/2018Rajesh C Md ShrotriyaDirectorSell30,000$19.93$597,900.00200,652View SEC Filing  
4/11/2018Rajesh C Md ShrotriyaDirectorSell30,000$20.30$609,000.00200,652View SEC Filing  
4/9/2018Rajesh C Md ShrotriyaDirectorSell12,300$15.01$184,623.00200,652View SEC Filing  
4/6/2018Rajesh C Md ShrotriyaDirectorSell3,686$15.00$55,290.00200,652View SEC Filing  
4/4/2018Rajesh C Md ShrotriyaDirectorSell30,000$15.01$450,300.00200,652View SEC Filing  
4/2/2018Rajesh C Md ShrotriyaDirectorSell60,000$15.90$954,000.00200,652View SEC Filing  
4/2/2018Thomas J RigaCOOSell1,948$15.58$30,349.84256,452View SEC Filing  
3/28/2018Joseph W TurgeonCEOSell4,810$16.40$78,884.00328,074View SEC Filing  
3/28/2018Kurt A GustafsonCFOSell4,350$16.35$71,122.50187,193View SEC Filing  
3/28/2018Rajesh C Md ShrotriyaDirectorSell90,000$16.88$1,519,200.00200,652View SEC Filing  
3/26/2018Kurt A GustafsonCFOSell1,300$17.38$22,594.00191,543View SEC Filing  
3/26/2018Rajesh C Md ShrotriyaDirectorSell30,000$17.34$520,200.00200,652View SEC Filing  
3/26/2018Thomas J RigaCOOSell220$17.41$3,830.20251,476View SEC Filing  
3/22/2018Joseph W TurgeonCEOSell3,100$18.17$56,327.00332,884View SEC Filing  
3/22/2018Kurt A GustafsonCFOSell2,640$18.13$47,863.20192,843View SEC Filing  
3/21/2018Stuart Mitchell KrassnerDirectorSell4,200$18.64$78,288.0083,257View SEC Filing  
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines

Source:
DateHeadline
Spectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from BrokeragesSpectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 21 at 5:33 PM
OncoMed Pharmaceuticals: Assessing The Prospect Of A Potential Robust WinnerOncoMed Pharmaceuticals: Assessing The Prospect Of A Potential Robust Winner
seekingalpha.com - May 21 at 8:14 AM
Spectrum Pharmaceuticals (SPPI) Director Sells $399,880.22 in StockSpectrum Pharmaceuticals (SPPI) Director Sells $399,880.22 in Stock
www.americanbankingnews.com - May 18 at 7:53 PM
Spectrum Pharma up 17% on late-stage Rolontis dataSpectrum Pharma up 17% on late-stage Rolontis data
seekingalpha.com - May 17 at 6:46 PM
Why Spectrum Pharmaceuticals, Inc. Is Up Big TodayWhy Spectrum Pharmaceuticals, Inc. Is Up Big Today
www.fool.com - May 17 at 1:40 PM
Spectrum Pharma (SPPI) Highlights Detailed Results from Phase 3 Study of ROLONTIS (eflapegrastim) Published in ASCO AbstractSpectrum Pharma (SPPI) Highlights Detailed Results from Phase 3 Study of ROLONTIS (eflapegrastim) Published in ASCO Abstract
www.streetinsider.com - May 17 at 8:19 AM
CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO AbstractCORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
finance.yahoo.com - May 17 at 8:19 AM
Spectrum Pharmaceuticals (SPPI) Lifted to "Buy" at Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 2:09 PM
Spectrum Pharmaceuticals (SPPI) COO Thomas J. Riga Sells 3,290 SharesSpectrum Pharmaceuticals (SPPI) COO Thomas J. Riga Sells 3,290 Shares
www.americanbankingnews.com - May 14 at 8:16 PM
Rajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) StockRajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - May 14 at 4:15 PM
Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 24,014 Shares of StockInsider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 24,014 Shares of Stock
www.americanbankingnews.com - May 14 at 4:15 PM
Zacks Investment Research Lowers Spectrum Pharmaceuticals (SPPI) to HoldZacks Investment Research Lowers Spectrum Pharmaceuticals (SPPI) to Hold
www.americanbankingnews.com - May 14 at 12:13 PM
Spectrum Pharmaceuticals (SPPI) Upgraded to "Sell" by BidaskClubSpectrum Pharmaceuticals (SPPI) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - May 11 at 8:53 PM
Spectrum Pharmaceuticals (SPPI) Upgraded by Zacks Investment Research to "Buy"Spectrum Pharmaceuticals (SPPI) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 9 at 6:47 PM
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16thSpectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th
finance.yahoo.com - May 9 at 8:16 AM
Zacks Investment Research Downgrades Spectrum Pharmaceuticals (SPPI) to SellZacks Investment Research Downgrades Spectrum Pharmaceuticals (SPPI) to Sell
www.americanbankingnews.com - May 7 at 1:13 PM
Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of PoziotinibBlog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib
finance.yahoo.com - May 7 at 8:18 AM
Spectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $27.55 MillionSpectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $27.55 Million
www.americanbankingnews.com - May 7 at 1:58 AM
-$0.21 EPS Expected for Spectrum Pharmaceuticals (SPPI) This Quarter-$0.21 EPS Expected for Spectrum Pharmaceuticals (SPPI) This Quarter
www.americanbankingnews.com - May 5 at 11:14 PM
Spectrum Pharmaceuticals (SPPI) Posts Quarterly  Earnings Results, Beats Estimates By $0.19 EPSSpectrum Pharmaceuticals (SPPI) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS
www.americanbankingnews.com - May 4 at 5:55 PM
Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 90,000 Shares of StockInsider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 90,000 Shares of Stock
www.americanbankingnews.com - May 4 at 4:37 PM
Spectrum Pharmaceuticals (SPPI) CEO Joe Turgeon on Q1 2018 Results - Earnings Call TranscriptSpectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:17 AM
Edited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 8:17 AM
Spectrum Pharmaceuticals beats by $0.20, beats on revenueSpectrum Pharmaceuticals beats by $0.20, beats on revenue
seekingalpha.com - May 3 at 5:26 PM
Spectrum Pharma in-licenses IP related to certain uses of poziotinibSpectrum Pharma in-licenses IP related to certain uses of poziotinib
seekingalpha.com - May 3 at 5:26 PM
Spectrum Pharma: 1Q Earnings SnapshotSpectrum Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:26 PM
Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline UpdateSpectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update
finance.yahoo.com - May 3 at 5:26 PM
Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer CenterSpectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
finance.yahoo.com - May 3 at 8:13 AM
Spectrum Pharmaceuticals (SPPI) to Release Earnings on ThursdaySpectrum Pharmaceuticals (SPPI) to Release Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:10 PM
Spectrum Pharmaceuticals (SPPI) Upgraded to Strong-Buy at ValuEngineSpectrum Pharmaceuticals (SPPI) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM
Spectrum Pharmaceuticals (SPPI) Lowered to "Strong Sell" at BidaskClubSpectrum Pharmaceuticals (SPPI) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - May 2 at 12:02 PM
Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 SharesSpectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 Shares
www.americanbankingnews.com - May 1 at 7:18 PM
Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of StockInsider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of Stock
www.americanbankingnews.com - May 1 at 7:18 PM
Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target TestThermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test
www.prnewswire.com - May 1 at 8:22 AM
Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo ...Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo ...
www.businesswire.com - May 1 at 8:22 AM
BRIEF-Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With ...BRIEF-Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With ...
www.reuters.com - May 1 at 8:22 AM
Spectrum Pharma rescinds poison pill provision, reshuffles board; shares down 4%Spectrum Pharma rescinds poison pill provision, reshuffles board; shares down 4%
seekingalpha.com - April 30 at 5:15 PM
Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board ChangesSpectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes
finance.yahoo.com - April 30 at 8:21 AM
Spectrum Pharmaceuticals (SPPI) Short Interest UpdateSpectrum Pharmaceuticals (SPPI) Short Interest Update
www.americanbankingnews.com - April 27 at 3:42 AM
Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 SharesSpectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 Shares
www.americanbankingnews.com - April 26 at 7:12 PM
Spectrum Pharmaceuticals (SPPI) Given Consensus Recommendation of "Hold" by AnalystsSpectrum Pharmaceuticals (SPPI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 26 at 5:36 PM
Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and WebcastSpectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast
finance.yahoo.com - April 26 at 8:15 AM
Form 4 SPECTRUM PHARMACEUTICALS For: Apr 19 Filed by: SHROTRIYA RAJESH C MDForm 4 SPECTRUM PHARMACEUTICALS For: Apr 19 Filed by: SHROTRIYA RAJESH C MD
www.streetinsider.com - April 24 at 8:18 AM
Spectrum Pharma (SPPI) Reports Publication of Poziotinib DataSpectrum Pharma (SPPI) Reports Publication of Poziotinib Data
www.streetinsider.com - April 24 at 8:18 AM
Zacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 MillionZacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 Million
www.americanbankingnews.com - April 20 at 1:06 AM
Spectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other CancersSpectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers
www.streetinsider.com - April 19 at 8:13 AM
 Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS
www.americanbankingnews.com - April 18 at 11:22 PM
Spectrum Pharmaceuticals (SPPI) CEO Sells $219,735.00 in StockSpectrum Pharmaceuticals (SPPI) CEO Sells $219,735.00 in Stock
www.americanbankingnews.com - April 18 at 7:46 PM
Rajesh C. Md Shrotriya Sells 90,000 Shares of Spectrum Pharmaceuticals (SPPI) StockRajesh C. Md Shrotriya Sells 90,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 18 at 7:16 PM
Spectrum Pharmaceuticals: What To Expect From This Powerful GrowerSpectrum Pharmaceuticals: What To Expect From This Powerful Grower
seekingalpha.com - April 18 at 8:15 AM

SEC Filings

Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.